Regencell Bioscience (RGC) Stock Statistics & Valuation Metrics

Regencell Bioscience has a market cap or net worth of $5.12B. The enterprise value is $11.35B.

Regencell Bioscience has 494,488,920 shares outstanding. The number of shares has decreased by -2.65% in one year.

Regencell Bioscience’s return on equity (ROE) is -0.52 and return on invested capital (ROIC) is -57.04%.

The current PE Ratio of Regencell Bioscience is -9.71. Regencell Bioscience’s PEG ratio is -336.04.

In the last 12 months, Regencell Bioscience had revenue of 0.00 and earned -4.30M in profits. Earnings per share was -0.01.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Regencell Bioscience pays an annual dividend of $0.22, resulting in a dividend yield of ―

Regencell Bioscience upcoming earnings date is ―, ―.

Regencell Bioscience as a current ratio of 41.92, with Debt / Equity ratio of 1.04%

In the past 12 months, Regencell Bioscience has paid 0.00 in taxes.

Regencell Bioscience EV to EBITDA ratio is -10.75, with an EV/FCF ratio of -9.71.

Regencell Bioscience has $7.96M in cash and marketable securities with $85.74K in debt, giving a net cash position of -$7.88M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Regencell Bioscience is ―, which is 11.43% higher than the current price. The consensus rating is ―